BACKGROUND: Brain metastases (BM) of gastro-oesophageal cancer are exceedingly rare and only limited data exist on their pathobiology. MATERIALS AND METHODS: We identified tissue samples of BM of gastro-oesophageal cancer and analyzed the expression of human epidermal growth factor receptor-2 (HER2), phosphorylated signal transducer and activator of transcription-3 (pSTAT3), epithelial growth factor receptor (EGFR), V600E point mutation of the v-raf murine sarcoma viral oncogene homolog-B1 (BRAF V600E), cluster of differentiation molecule-34 (CD34), hypoxia inducible factor-1α (HIF 1-α) and Ki-67 by immunohistochemical methods. RESULTS: Our series comprised of twenty adenocarcinomas and one oesophageal squamous cell carcinoma. Three (14%), 7 (33%), 9 (43%), 18 (86%) and 0 BM specimens were scored positively for HER2, EGFR, pSTAT3, HIF1-α and BRAF V600E expression. The median Ki-67 index was 59%. The microvascular density was moderate-to-high and active intratumoral microvascular sprouting was evident in 20/21 (95%) of BMs. The HER2 and EGFR expression status were consistent between primary tumors and BM in all three assessable cases. HIF1-α and pSTAT3 expression were significantly higher in HER2-positive cases. CONCLUSION: Therapeutic use of agents targeting HER2, pSTAT3, EGFR and angiogenesis may be feasible for selected BM of gastro-esophageal cancer. HER2 positivity does not seem to predispose to brain colonization in gastro-esophageal cancer.
BACKGROUND: Brain metastases (BM) of gastro-oesophageal cancer are exceedingly rare and only limited data exist on their pathobiology. MATERIALS AND METHODS: We identified tissue samples of BM of gastro-oesophageal cancer and analyzed the expression of human epidermal growth factor receptor-2 (HER2), phosphorylated signal transducer and activator of transcription-3 (pSTAT3), epithelial growth factor receptor (EGFR), V600E point mutation of the v-raf murine sarcoma viral oncogene homolog-B1 (BRAFV600E), cluster of differentiation molecule-34 (CD34), hypoxia inducible factor-1α (HIF 1-α) and Ki-67 by immunohistochemical methods. RESULTS: Our series comprised of twenty adenocarcinomas and one oesophageal squamous cell carcinoma. Three (14%), 7 (33%), 9 (43%), 18 (86%) and 0 BM specimens were scored positively for HER2, EGFR, pSTAT3, HIF1-α and BRAFV600E expression. The median Ki-67 index was 59%. The microvascular density was moderate-to-high and active intratumoral microvascular sprouting was evident in 20/21 (95%) of BMs. The HER2 and EGFR expression status were consistent between primary tumors and BM in all three assessable cases. HIF1-α and pSTAT3 expression were significantly higher in HER2-positive cases. CONCLUSION: Therapeutic use of agents targeting HER2, pSTAT3, EGFR and angiogenesis may be feasible for selected BM of gastro-esophageal cancer. HER2 positivity does not seem to predispose to brain colonization in gastro-esophageal cancer.
Authors: Nishi Kothari; Eric Mellon; Sarah E Hoffe; Jessica Frakes; Ravi Shridhar; Jose Pimiento; Ken Meredith; Nam D Tran; Nadia Saeed; Khaldoun Almhanna Journal: J Gastrointest Oncol Date: 2016-08
Authors: Devarati Mitra; Jeffrey W Clark; Helen A Shih; Kevin S Oh; Priscilla K Brastianos; Jennifer Y Wo; Matthew R Strickland; William T Curry; Aparna R Parikh; Ryan B Corcoran; David P Ryan; A John Iafrate; Darrell R Borger; Jochen K Lennerz; Theodore S Hong Journal: Oncologist Date: 2018-10-29
Authors: Yoshiaki Shoji; Satoru Furuhashi; Daniel F Kelly; Anton J Bilchik; Dave S B Hoon; Matias A Bustos Journal: Clin Exp Metastasis Date: 2021-05-05 Impact factor: 5.150
Authors: J Feilchenfeldt; Z Varga; M Siano; H I Grabsch; U Held; B Schuknecht; A Trip; T Hamaguchi; P Gut; O Balague; K Khanfir; J Diebold; W Jochum; H Shoji; R Kushima; D Wagner; Y Shimada; A Cats; A Knuth; H Moch; S Aebi; S Hofer Journal: Br J Cancer Date: 2015-08-27 Impact factor: 7.640